Intensive glycemic control is not associated with fractures or falls in the ACCORD randomized trial.
about
The alliance of mesenchymal stem cells, bone, and diabetesGlucagon-like peptide-1 receptor agonist Liraglutide has anabolic bone effects in ovariectomized rats without diabetesDiabetes, bone and glucose-lowering agents: clinical outcomes.Epidemiology of Fractures in Diabetes.Skeletal Metabolism, Fracture Risk, and Fracture Outcomes in Type 1 and Type 2 Diabetes.Diabetes mellitus and risk of falls in older adults: a systematic review and meta-analysis.Achieving glycemic control in elderly patients with type 2 diabetes: a critical comparison of current options.Intensive blood pressure control, falls, and fractures in patients with type 2 diabetes: the ACCORD trialThe role of osteocalcin in human glucose metabolism: marker or mediator?Change in estimated glomerular filtration rate and fracture risk in the Action to Control Cardiovascular Risk in Diabetes TrialGlycemic Control with Thiazolidinedione Is Associated with Fracture of T2DM Patients.Association Between History of Severe Hypoglycemia and Risk of Falls in Younger and Older Patients With Diabetes.Determinants of bone strength and quality in diabetes mellitus in humans.Effects of TZD Use and Discontinuation on Fracture Rates in ACCORD Bone StudyA growing troubling triad: diabetes, aging, and falls.Diabetes and risk of fracture-related hospitalization: the Atherosclerosis Risk in Communities Study.Intensive glycemic control and thiazolidinedione use: effects on cortical and trabecular bone at the radius and tibia.High bone mineral density and fracture risk in type 2 diabetes as skeletal complications of inadequate glucose control: the Rotterdam StudyType 1 diabetes and risk of fracture: meta-analysis and review of the literature.Glycemic control and fracture risk in elderly patients with diabetes.Effects of randomization to intensive glucose control on adverse events, cardiovascular disease, and mortality in older versus younger adults in the ACCORD Trial.In vivo assessment of bone quality in postmenopausal women with type 2 diabetes.Type 2 diabetes and bone.Antidiabetic therapy effects on bone metabolism and fracture risk.The prevention of fragility fractures in diabetic patients.Visit-to-visit variation of fasting plasma glucose is a predictor of hip fracture in older persons with type 2 diabetes: the Taiwan Diabetes Study.Considerations on glycaemic control in older and/or frail individuals with diabetes and advanced kidney disease.Sitagliptin and risk of fractures in type 2 diabetes: Results from the TECOS trial.Glycated Hemoglobin Level and Risk of Hip Fracture in Older People with Type 2 Diabetes: A Competing Risk Analysis of Taiwan Diabetes Cohort Study.Comparative Effectiveness for Glycemic Control in Older Adults with Diabetes.Trends in incidence of proximal humerus fractures, surgical procedures and outcomes among elderly hospitalized patients with and without type 2 diabetes in Spain (2001-2013).Skeletal fragility in diabetes.Diabetes mellitus and bone health: epidemiology, etiology and implications for fracture risk stratification.Skeletal Fragility in Type 2 Diabetes Mellitus
P2860
Q27012497-4B8EF55D-ECE2-47E4-B9AF-416EA025EABAQ28546539-6C494A36-65AC-438D-B9FA-2547C99EED12Q30234622-495D3782-DC20-4BFD-B3C3-0790BD99DD4EQ30248863-E82E7A7D-982E-4B06-A395-AAE025684590Q30249436-0A092673-1DFA-4F6E-9977-24635A082ACCQ34537099-8A4040C4-D745-4D68-8B61-7D163BE0AA47Q34563587-D358D765-4A3D-4E2A-8324-EC65BEF173B6Q34566902-04C9F96E-2D70-4BEE-ACAC-585CCF3036E1Q35636353-E4F349D6-E21D-4055-93FA-C7602394E60DQ35739081-4BF3704E-BDED-4BC2-91C4-B97C851FAE13Q35759258-BE91552C-C7D0-449B-BECF-895127244925Q36194085-53DB402E-16C9-421A-93C7-73EB6E62B81CQ36373016-390D0A2D-A0DB-4A79-98D9-B8D8293496D7Q36433551-69B7E6DA-BB31-4A95-8A6D-7C8C2007C14BQ36651355-35D31835-4598-40A8-836C-DC1815FC7C6BQ36782841-8B1AEF48-41BC-4ED5-9359-41B2BDCAB139Q36807306-31949F17-E737-44D5-84B7-750155EF526AQ36868093-06C42672-33CE-45C7-BDBA-467C5BFE2C97Q36883007-C3132422-CFB8-41F2-9C4F-C4B543FE393BQ37060219-B696B9BD-2398-45E1-A1FB-4ACE4F074EE7Q37597008-3DD077BE-39A7-4DCF-A482-D370F94F3BE8Q37652868-72221DF3-518E-4881-9061-2969B4188849Q38048186-59F3FD80-585E-4486-AF18-114E8B2A17C6Q38078009-5391CA08-A445-4BDB-9C60-FB76CB013EC6Q38233593-939647CA-343D-43C7-802F-0B28F3A21EA9Q38846674-65B05FAD-E9C0-45E6-8924-714AE9E6F740Q38878430-456303AF-E2D4-4EB7-B405-BDD744D10D2FQ39410329-023750A3-64EC-45EC-BCEC-6F2C25081C02Q41566308-99BA89CA-B817-49BC-8EED-FC8721C72103Q41852283-EB9AE740-4F02-453B-9F95-F58107921B0FQ47135624-D5546C17-0E50-4535-8766-E3891CE29427Q50021725-257A765E-EF25-4401-AA16-B92CB3EDAD2AQ55000563-C34D8E34-7A58-459F-A277-64967F9F8401Q58725004-5DDBE4F3-3BB0-473E-BA91-CEC2929808F5
P2860
Intensive glycemic control is not associated with fractures or falls in the ACCORD randomized trial.
description
2012 nî lūn-bûn
@nan
2012年の論文
@ja
2012年論文
@yue
2012年論文
@zh-hant
2012年論文
@zh-hk
2012年論文
@zh-mo
2012年論文
@zh-tw
2012年论文
@wuu
2012年论文
@zh
2012年论文
@zh-cn
name
Intensive glycemic control is ...... n the ACCORD randomized trial.
@ast
Intensive glycemic control is ...... n the ACCORD randomized trial.
@en
type
label
Intensive glycemic control is ...... n the ACCORD randomized trial.
@ast
Intensive glycemic control is ...... n the ACCORD randomized trial.
@en
prefLabel
Intensive glycemic control is ...... n the ACCORD randomized trial.
@ast
Intensive glycemic control is ...... n the ACCORD randomized trial.
@en
P2093
P2860
P356
P1433
P1476
Intensive glycemic control is ...... n the ACCORD randomized trial.
@en
P2093
Adrian M Schnall
Ann V Schwartz
Bruce P Hamilton
Deborah E Sellmeyer
Debra L Simmons
Denise E Bonds
Douglas C Bauer
Hal H Atkinson
Jennifer B Green
Karen L Margolis
P2860
P304
P356
10.2337/DC11-2184
P407
P577
2012-07-01T00:00:00Z